A Phase 1/2 Randomized, Blinded, Placebo Controlled Study of Ipilimumab in Combination With Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma
Clinical trial NCT01604889 · TERMINATED
Trial details
- NCT number
- NCT01604889
- Sponsor
- Incyte Corporation
- Status
- TERMINATED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2012-03-29
- Primary completion
- 2016-12-27
- Enrollment
- 50
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.